全部文献期刊学位论文会议报纸专利标准年鉴图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Helen Swaisland , Henk M.W. Verheul ...
来源:[J].Clinical Therapeutics(IF 2.23), 2016, Vol.38 (10), pp.2286-2299Elsevier
摘要:Abstract(#br)Purpose(#br)The metabolism of olaparib, a potent inhibitor of poly(ADP-ribose) polymerase (PARP) with demonstrated efficacy in patients with BRCA -mutated ovarian cancer, is mediated by cytochrome P450 (CYP) enzymes (predominantly CYP3A4/5). We assessed the pote...
作者:Helen Swaisland , Karin Leunen ...
来源:[J].Advances in Therapy(IF 2.125), 2015, Vol.32 (6), pp.510-522Springer
摘要:Abstract(#br) Background(#br)The oral, potent poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib, is well tolerated at doses of ≤400 mg twice daily (BID) (administered as capsules), and has shown efficacy in patients with advanced BRCA -mutated ovarian and breast cancer....
作者:Helen Swaisland , Ruth Plummer ...
来源:[J].Cancer Chemotherapy and Pharmacology(IF 2.795), 2016, Vol.78 (4), pp.775-784Springer
摘要:Abstract(#br) Background(#br)Some therapeutic agents in oncology can be causally associated with specific cardiovascular events including QT/QTc interval prolongation. We investigated the effect of multiple dosing of the oral poly (ADP-ribose)-polymerase (PARP) in...
作者:Helen Swaisland , Karin Leunen ...
来源:[J].Cancer Chemotherapy and Pharmacology(IF 2.795), 2015, Vol.76 (4), pp.723-729Springer
摘要:Abstract(#br) Background(#br)The oral PARP inhibitor olaparib has shown efficacy in patients with BRCA -mutated cancer. This Phase I, open-label, three-part study (Parts A–C) in patients with advanced solid tumours evaluated the effect of food on the pharmacokinetics (PK) of...
作者:Helen Swaisland , Venkatesh Pilla Reddy ...
来源:[J].Xenobiotica(IF 1.984), 2018, Vol.48 (6), pp.555-564Taylor & Francis
摘要:Abstract(#br)1. In vitro studies were conducted to evaluate potential inhibitory and inductive effects of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib, on cytochrome P450 (CYP) enzymes. Inhibitory effects were determined in human liver microsomes (HLM); inducti...
作者:Helen Swaisland , Maria Cavallin ...
来源:[J].Investigational New Drugs(IF 3.498), 2013, Vol.31 (4), pp.949-958Springer
摘要:Summary(#br)Olaparib (AZD2281) is an oral poly(ADP-ribose) polymerase (PARP) inhibitor with antitumour activity in cancer patients with BRCA1/2 germline mutations and in patients with homologous recombination deficiency. In this dose-finding study, patients were randomized t...
作者:Alex McCormick , Helen Swaisland
来源:[J].Xenobiotica(IF 1.984), 2017, Vol.47 (10), pp.903-915Taylor & Francis
摘要:Abstract(#br)1. In vitro assessments were conducted to examine interactions between olaparib (a potent oral inhibitor of poly[ADP-ribose] polymerase) and drug transporters.(#br)2. Olaparib showed inhibition of the hepatic drug uptake transporters OATP1B1 (IC50 val...
作者:Helen Swaisland , Matthew R. Farmer ...
来源:[J].International Journal of Pharmaceutics(IF 3.458), 2007, Vol.341 (1), pp.134-142Elsevier
摘要:Abstract(#br)Purpose(#br)To investigate whether differences in plasma pharmacokinetic profiles of gefitinib between healthy subjects having normal (N; t 1/2 > 20 h) and altered (A; t 1/2 < 20 h) pharmacokinetic (PK) profiles might be explained by inter-individual variabili...
作者:... Alan Swaisland , Helen Swaisland , Chris Twelves
来源:[J].Cancer Chemotherapy and Pharmacology(IF 2.795), 2011, Vol.68 (6), pp.1485-1495Springer
摘要:Abstract(#br) Purpose(#br)We investigated whether the pharmacokinetics and tolerability of gefitinib were altered in patients with hepatic impairment due to cirrhosis or hepatic metastases in two open, parallel-group, multicenter studies.(#br) Methods(#br)In Study 1, subject...
作者:... Salvatore Febbraro , Helen Swaisland , Andrew Hughes
来源:[J].Cancer Chemotherapy and Pharmacology(IF 2.795), 2007, Vol.60 (3), pp.391-398Springer
摘要:Abstract(#br)AZD5438 is a novel cyclin-dependent kinase inhibitor with preclinical pharmacodynamic (PD) activity against a range of human tumour xenografts. A first-in-man tolerability and pharmacokinetic (PK) study involving single ascending doses of AZD5438 was conducted i...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×